期刊文献+

利格列汀联合二甲双胍治疗初诊2型糖尿病患者的疗效研究 被引量:5

下载PDF
导出
摘要 目的探讨利格列汀联合二甲双胍治疗初诊2型糖尿病患者的疗效。方法回顾性2015年1月至2017年3月在我院进行治疗的60例2型糖尿病患者的临床资料,随机将其分为两组,观察组和对照组,各有30例患者。对照组采用口服安慰剂和二甲双胍联合治疗,观察组采用利格列汀联合二甲双胍联合治疗。比较两组患者经过不同药物治疗后的效果以及出现不良反应的情况。结果观察组的治疗总有效率为96.7%,对照组患者的治疗总有效率为83.3%,观察组的治疗总有效率显著高于对照组,差异具有统计学意义(P <0.05);观察组不良反应的发生率为20.0%,对照组不良反应的发生率为32.0%,观察组的不良反应发生情况显著优于对照组,差异具有统计学意义(P<0.05)。结论利格列汀联合二甲双胍治疗初诊2型糖尿病患者的治疗效果显著,具有较高的安全性,值得应用于临床推广。
作者 戴一姝
出处 《中国医药指南》 2018年第33期156-156,共1页 Guide of China Medicine
  • 相关文献

参考文献3

二级参考文献37

  • 1Giugliano D, Standl E, Vilsboll T, et al. Is the current therapeutic ar- mamentarium in diabetes enough to control the epidemic and its conse- quences? What are the current shortcomings? [ J ]. Acta Diabetol, 2009, 46(3) : 173 -181.
  • 2Nauck M A. Unraveling the science of incretin biology [ J]. Eur J In- tern Med, 2009, 20( Suppl 2) : S303 -S308.
  • 3Gupta N A, Mells J, Dunham R M, et al. Glucagon-like peptide-I re- ceptor is present on human hepatocytes and has a direct role in decrea- sing hepatic steatosis in vitro by modulating elements of the insulin sig- naling pathway [J]. Hepatology, 2010, 51 (5): 1584- 1592.
  • 4Nathan D M, Buse J B, Davidson M B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initia- tion and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Dia- betes [J]. Diabetes Care, 2009, 32( 1 ) : 193 -203.
  • 5Eng J, Kleinman W A, Singh L, et al. Isolation and characterization of exendin-.4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas I J]. J Biol Chem, 1992, 267( 11 ): 7402-7405.
  • 6Boulton D, Tang A, Patel C, et al. Pharmaeokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment [ J]. Endocr Abstr, 2009, 20: 357.
  • 7Yu Z, Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 ( GLP-1 ) [ J].Cell Signal, 2010, 22(1) : 1 -8.
  • 8Fehse F, Trautmann M, Hoist J J, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [ J]. J Clin Endocrinol Metab, 2005,90 (11) : 5991 -5997.
  • 9Buse J B, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised, par- allel-group, multinational, open-label trial ( LEAD-6 ) [ J ]. Lancet, 2009, 374(9683): 39-47.
  • 10Erdogdu O, Nathanson D, Sjoholm A, et al. Exendin4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor[J]. Mol Cell Endocrinol, 2010, 325( 1/2): 26-35.

共引文献41

同被引文献40

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部